Zacks: Analysts Set $48.00 Price Target for Innophos Holdings, Inc. (IPHS)

Shares of Innophos Holdings, Inc. (NASDAQ:IPHS) have received an average broker rating score of 2.00 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company. Innophos’ rating score has improved by 33.3% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.

Brokerages have set a 12-month consensus price objective of $48.00 for the company and are expecting that the company will post $0.35 EPS for the current quarter, according to Zacks. Zacks has also given Innophos an industry rank of 175 out of 256 based on the ratings given to its competitors.

IPHS has been the topic of several research reports. BidaskClub upgraded Innophos from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. Seaport Global Securities initiated coverage on Innophos in a research note on Thursday, February 21st. They set a “buy” rating on the stock. ValuEngine upgraded Innophos from a “strong sell” rating to a “sell” rating in a research note on Monday, February 4th. TheStreet upgraded Innophos from a “c” rating to a “b-” rating in a research note on Thursday, February 21st. Finally, Zacks Investment Research lowered Innophos from a “hold” rating to a “sell” rating in a research note on Saturday, March 2nd.

Innophos stock opened at $31.77 on Friday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.49 and a current ratio of 3.14. The stock has a market capitalization of $624.52 million, a PE ratio of 13.93 and a beta of 1.33. Innophos has a 52 week low of $22.57 and a 52 week high of $50.40.

Innophos (NASDAQ:IPHS) last posted its quarterly earnings data on Tuesday, April 30th. The specialty chemicals company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.14. The business had revenue of $191.41 million for the quarter, compared to analyst estimates of $199.90 million. Innophos had a return on equity of 13.09% and a net margin of 4.30%. The firm’s revenue for the quarter was down 6.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.61 earnings per share. Analysts anticipate that Innophos will post 2.36 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a dividend of $0.48 per share. The ex-dividend date is Thursday, May 16th. This represents a $1.92 annualized dividend and a yield of 6.04%. Innophos’s dividend payout ratio is 84.21%.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. increased its stake in Innophos by 0.7% during the first quarter. BlackRock Inc. now owns 2,951,513 shares of the specialty chemicals company’s stock valued at $88,958,000 after acquiring an additional 19,339 shares during the period. Vanguard Group Inc. boosted its holdings in Innophos by 2.0% during the third quarter. Vanguard Group Inc. now owns 2,065,439 shares of the specialty chemicals company’s stock valued at $91,705,000 after purchasing an additional 41,101 shares in the last quarter. Vanguard Group Inc boosted its holdings in Innophos by 2.0% during the third quarter. Vanguard Group Inc now owns 2,065,439 shares of the specialty chemicals company’s stock valued at $91,705,000 after purchasing an additional 41,101 shares in the last quarter. Segall Bryant & Hamill LLC boosted its holdings in Innophos by 48.3% during the fourth quarter. Segall Bryant & Hamill LLC now owns 1,707,840 shares of the specialty chemicals company’s stock valued at $41,893,000 after purchasing an additional 556,531 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Innophos by 3.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,084,227 shares of the specialty chemicals company’s stock valued at $26,596,000 after purchasing an additional 38,309 shares in the last quarter. Hedge funds and other institutional investors own 92.13% of the company’s stock.

About Innophos

Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.

Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.